

Effective Drug Therapy For Hyperlipidemia

It is now the consensus that drug therapy of hyperlipidemia should be preceded by specific diagnosis. Primary hyperlipoproteinemia due to one of the five phenotypes should be differentiated from secondary hyperlipidemia due to myxedema, diabetes, etc. Secondary hyperlipidemia is treated by treating the underlying cause. Of the primary Types, I responds to low fat diet; II responds to a polyunsaturated fat diet plus oral bile acid bind-

ing resin therapy; III responds to weight loss and Clofibrate; IV responds to dietary restriction of carbohydrate, and Clofibrate; and V is a mixed classification. No single agent appears suitable for all Type V patients.

DAVID H. BLANKENHORN, M.D.

REFERENCES

- Fredrickson DS, Levy RI, Lees RS: Fat transport in lipoproteins — An integrated approach to mechanisms and disorders. *New Eng J Med* 276:34-42, 94-103, 148-156, 215-225, 273-281, 1967
Levy RI, Fredrickson DS: Diagnosis and management of hyperlipoproteinemia. *Amer J Cardiol* 22:576-583, 1968

ADVISORY PANEL SECTION ON INTERNAL MEDICINE

LEYLAND E. STEVENS, M.D., Chairman
San Francisco
Chairman of CMA Section on Internal Medicine

J. EDWARD BERK, M.D.
University of California, Irvine,
California College of Medicine

ROBERT J. BOLT, M.D.
University of California, Davis,
School of Medicine

EUGENE BRAUNWALD, M.D.
University of California, San Diego,
School of Medicine

THOMAS H. BREM, M.D.
University of Southern California
School of Medicine
Los Angeles

W. PHILLIP CORR, SR., M.D.
American College of Physicians,
Southern California Region
Riverside

JOHN GAMBLE, M.D.
American College of Physicians,
Northern California and Nevada Region
San Francisco

HALSTED R. HOLMAN, M.D.
Stanford University School of Medicine

VARNER J. JOHNS, M.D.
Loma Linda University School of Medicine

M. GLENN MOLYNEAUX, M.D.
CMA Section on Internal Medicine, Assistant Secretary
San Francisco

DONALD W. PETIT, M.D.
CMA Scientific Board
Alhambra

GLENN A. POPE, M.D.
CMA Scientific Board
Sacramento

PETTUS G. SECREST, M.D.
CMA Section on Internal Medicine, Secretary
Long Beach

LLOYD H. SMITH, JR., M.D.
University of California, San Francisco Medical Center

WILLIAM A. TODD, M.D.
California Society of Internal Medicine, Trustee
Long Beach

W. N. VALENTINE, M.D.
University of California, Los Angeles,
School of Medicine